Literature DB >> 21907867

Controversies in treatment of chronic obstructive pulmonary disease.

Klaus F Rabe1, Jadwiga A Wedzicha.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a chronic disorder with substantial comorbidity and major effects attributable to the high morbidity and mortality rates. Despite an increasing evidence base, some important controversies in COPD management still exist. The classic way to define COPD has been based on spirometric criteria, but more relevant diagnostic methods are needed that can be used to describe COPD severity and comorbidity. Initiation of interventions earlier in the natural history of the disease to slow disease progression is debatable, there are many controversies about the role of inhaled corticosteroids in the management of COPD, and long-term antibiotics for prevention of exacerbation have had a resurgence in interest. Novel therapeutic drugs are urgently needed for optimum management of the acute COPD exacerbation. COPD is a complex disease and consists of several clinically relevant phenotypes that in future will guide its management.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907867     DOI: 10.1016/S0140-6736(11)61295-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  23 in total

1.  β-Adrenoceptor blockers and pulmonary function in the general population: the Rotterdam Study.

Authors:  Daan W Loth; Guy G Brusselle; Lies Lahousse; Albert Hofman; Hubert G M Leufkens; Bruno H Stricker
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

2.  Temporal trends in hospitalization rates for older adults with chronic obstructive pulmonary disease.

Authors:  Jacques Baillargeon; Yue Wang; Yong-Fang Kuo; Holly M Holmes; Gulshan Sharma
Journal:  Am J Med       Date:  2013-05-17       Impact factor: 4.965

3.  Anti-inflammatory role of the cAMP effectors Epac and PKA: implications in chronic obstructive pulmonary disease.

Authors:  Anouk Oldenburger; Sara S Roscioni; Esther Jansen; Mark H Menzen; Andrew J Halayko; Wim Timens; Herman Meurs; Harm Maarsingh; Martina Schmidt
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

4.  Predictors of treatment with antibiotics and systemic corticosteroids for acute exacerbations of asthma and chronic obstructive pulmonary disease in primary care.

Authors:  Al-ani Salwan; Mark Spigt; Johanna Laue; Hasse Melbye
Journal:  BMC Fam Pract       Date:  2015-03-24       Impact factor: 2.497

5.  Trends in the use, sociodemographic correlates, and undertreatment of prescription medications for chronic obstructive pulmonary disease among adults with chronic obstructive pulmonary disease in the United States from 1999 to 2010.

Authors:  Earl S Ford; David M Mannino; Anne G Wheaton; Letitia Presley-Cantrell; Yong Liu; Wayne H Giles; Janet B Croft
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

6.  Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications.

Authors:  Gillian E Caughey; Adrian K Preiss; Agnes I Vitry; Andrew L Gilbert; Elizabeth E Roughead
Journal:  Diabetes Care       Date:  2013-06-04       Impact factor: 19.112

7.  RECODE: design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary care.

Authors:  Annemarije L Kruis; Melinde R S Boland; Catharina H Schoonvelde; Willem J J Assendelft; Maureen P M H Rutten-van Mölken; Jacobijn Gussekloo; Apostolos Tsiachristas; Niels H Chavannes
Journal:  BMC Pulm Med       Date:  2013-03-23       Impact factor: 3.317

8.  COPD and disease-specific health status in a working population.

Authors:  Koichi Nishimura; Satoshi Mitsuma; Atsuko Kobayashi; Mikako Yanagida; Kazuhito Nakayasu; Yoshinori Hasegawa; Paul W Jones
Journal:  Respir Res       Date:  2013-06-02

9.  Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study.

Authors:  Annemarije L Kruis; Björn Ställberg; Rupert C M Jones; Ioanna G Tsiligianni; Karin Lisspers; Thys van der Molen; Jan Willem H Kocks; Niels H Chavannes
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

10.  Overtreatment of COPD with inhaled corticosteroids--implications for safety and costs: cross-sectional observational study.

Authors:  Patrick White; Hannah Thornton; Hilary Pinnock; Sofia Georgopoulou; Helen P Booth
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.